NASDAQ:PTCT PTC Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $45.46 -1.76 (-3.73 %) (As of 09/21/2020 12:00 AM ET) Add Compare Share Today's Range$45.16Now: $45.46▼$47.5550-Day Range$45.60MA: $48.08▼$50.4452-Week Range$30.79Now: $45.46▼$59.89Volume529,322 shsAverage Volume816,761 shsMarket Capitalization$3.08 billionP/E RatioN/ADividend YieldN/ABeta1.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.Read More Beat the Market (BTM) Rank™ 4.3 Analyst's Opinion Consensus RatingPTC Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $60.78, PTC Therapeutics has a forecasted upside of 33.7% from its current price of $45.46.Amount of Analyst CoveragePTC Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.5 Community Rank Outperform VotesPTC Therapeutics has received 502 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPTC Therapeutics has received 495 “underperform” votes. (Add your “underperform” vote.)Community SentimentPTC Therapeutics has received 50.35% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote “Outperform” if you believe PTCT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PTCT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPTC Therapeutics does not currently pay a dividend.Dividend GrowthPTC Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,570,118.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of PTC Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PTC Therapeutics are expected to grow in the coming year, from ($6.42) to ($2.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PTC Therapeutics is -6.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PTC Therapeutics is -6.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPTC Therapeutics has a P/B Ratio of 4.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTCT Previous Symbol CUSIPN/A CIK1070081 Webwww.ptcbio.com Phone908-222-7000Debt Debt-to-Equity Ratio0.56 Current Ratio3.00 Quick Ratio2.91Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$306.98 million Price / Sales10.03 Cash FlowN/A Price / Cash FlowN/A Book Value$9.64 per share Price / Book4.72Profitability EPS (Most Recent Fiscal Year)($3.45) Net Income$-251,580,000.00 Net Margins-138.67% Return on Equity-67.92% Return on Assets-25.49%Miscellaneous Employees511 Outstanding Shares67,703,000Market Cap$3.08 billion Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $45.46 -1.76 (-3.73 %) (As of 09/21/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PTCT News and Ratings via Email Sign-up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions How has PTC Therapeutics' stock price been impacted by Coronavirus? PTC Therapeutics' stock was trading at $47.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PTCT shares have decreased by 3.4% and is now trading at $45.46. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of PTC Therapeutics? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PTC Therapeutics. When is PTC Therapeutics' next earnings date? PTC Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for PTC Therapeutics. How were PTC Therapeutics' earnings last quarter? PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its quarterly earnings data on Wednesday, August, 5th. The biopharmaceutical company reported ($2.78) EPS for the quarter, missing the consensus estimate of ($1.29) by $1.49. The biopharmaceutical company had revenue of $75.24 million for the quarter, compared to the consensus estimate of $82.04 million. PTC Therapeutics had a negative net margin of 138.67% and a negative return on equity of 67.92%. The business's revenue for the quarter was down 12.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.75) EPS. View PTC Therapeutics' earnings history. What price target have analysts set for PTCT? 10 Wall Street analysts have issued 1-year target prices for PTC Therapeutics' shares. Their forecasts range from $45.00 to $86.00. On average, they anticipate PTC Therapeutics' stock price to reach $60.78 in the next year. This suggests a possible upside of 33.7% from the stock's current price. View analysts' price targets for PTC Therapeutics. Are investors shorting PTC Therapeutics? PTC Therapeutics saw a increase in short interest in August. As of August 14th, there was short interest totaling 6,290,000 shares, an increase of 22.4% from the July 30th total of 5,140,000 shares. Based on an average trading volume of 793,600 shares, the days-to-cover ratio is currently 7.9 days. View PTC Therapeutics' Short Interest. Who are some of PTC Therapeutics' key competitors? Some companies that are related to PTC Therapeutics include Dr.Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), GRIFOLS S A/S (GRFS), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), CureVac B.V. (CVAC), Jazz Pharmaceuticals (JAZZ), Mylan (MYL), Ascendis Pharma A/S (ASND), Mirati Therapeutics (MRTX), Ionis Pharmaceuticals (IONS), Myokardia (MYOK), ACADIA Pharmaceuticals (ACAD) and Perrigo (PRGO). View all competitors. What other stocks do shareholders of PTC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals PLC- (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Regulus Therapeutics (RGLS), Cisco Systems (CSCO), Aduro BioTech (ADRO) and Gilead Sciences (GILD). Who are PTC Therapeutics' key executives? PTC Therapeutics' management team includes the following people: Dr. Stuart W. Peltz, Co-Founder, CEO & Exec. Director (Age 59)Dr. Allan Steven Jacobson, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 73)Ms. Christine Utter, Principal Financial Officer & Treasurer (Age 41)Mr. Marcio Souza, Chief Operating Officer (Age 40)Dr. Neil Almstead, Chief Technical Operations Officer (Age 52) What is PTC Therapeutics' stock symbol? PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT." Who are PTC Therapeutics' major shareholders? PTC Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.38%), RTW Investments LP (5.85%), TimesSquare Capital Management LLC (1.52%), Macquarie Group Ltd. (1.38%), Candriam Luxembourg S.C.A. (1.18%) and Bank of New York Mellon Corp (1.10%). Company insiders that own PTC Therapeutics stock include Allan Steven Jacobson, Christine Marie Utter, Emily Luisa Hill, Marcio Souza, Mark Elliott Boulding, Michael Schmertzler, Neil Gregory Almstead and Stuart Walter Peltz. View institutional ownership trends for PTC Therapeutics. Which institutional investors are selling PTC Therapeutics stock? PTCT stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Nuveen Asset Management LLC, UBS Group AG, Caption Management LLC, Two Sigma Advisers LP, Asymmetry Capital Management L.P., Alps Advisors Inc., and Barclays PLC. Company insiders that have sold PTC Therapeutics company stock in the last year include Allan Steven Jacobson, Christine Marie Utter, Emily Luisa Hill, Marcio Souza, Mark Elliott Boulding, Neil Gregory Almstead, and Stuart Walter Peltz. View insider buying and selling activity for PTC Therapeutics. Which institutional investors are buying PTC Therapeutics stock? PTCT stock was purchased by a variety of institutional investors in the last quarter, including Bamco Inc. NY, Bank of New York Mellon Corp, Frontier Capital Management Co. LLC, Candriam Luxembourg S.C.A., Macquarie Group Ltd., Third Security LLC, Prudential Financial Inc., and Vanguard Group Inc.. View insider buying and selling activity for PTC Therapeutics. How do I buy shares of PTC Therapeutics? Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is PTC Therapeutics' stock price today? One share of PTCT stock can currently be purchased for approximately $45.46. How big of a company is PTC Therapeutics? PTC Therapeutics has a market capitalization of $3.08 billion and generates $306.98 million in revenue each year. The biopharmaceutical company earns $-251,580,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis. PTC Therapeutics employs 511 workers across the globe. What is PTC Therapeutics' official website? The official website for PTC Therapeutics is www.ptcbio.com. How can I contact PTC Therapeutics? PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected] This page was last updated on 9/22/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
